Gemcitabine and Carboplatin (renally dosed) regimen for bladder cancer.

Low-dose Gemcitabine and Carboplatin as a Good Palliation for Local Symptoms in Advanced Transitional Cell Carcinoma of Bladder

Progress in the management of metastatic bladder cancer.

BACKGROUND Inadequate survival results from single agents in the management of advanced bladder cancer have prompted several trials involving multidrug combinations to increase response rates and survival. METHODS Since the development of the MVAC regimen (methotrexate, vinblastine, doxorubicin, and cisplatin) and the CMV regimen (cisplatin, methotrexate, and vinblastine), other regimens have...

Bladder Metastasis of non-Small Cell Lung Cancer: an Unusual Cause of Hematuria

Approximately 2% of bladder malignancies are metastatic. The lung cancer makes metastasis sporadically to the bladder. A-69-year-old female patient presented with a history of pain in kidneys, vomiting and hematuria. Cystoscopic examination of the patient revealed small bladder capacity and solitary lesions in the bladder wall. Thoracic computed tomography scan identified multiple solid masses ...

Analysis of the cytotoxic activity of carboplatin and gemcitabine combination.

AIM To determine if the drug doses and administration schedules of carboplatin and gemcitabine combination affect antitumor effects. MATERIALS AND METHODS The inhibition of cell viability was measured by MTT assay. Median effect analysis was conducted to determine the cytotoxicity activity of carboplatin and gemcitabine combination. Cell cycle changes were analyzed by flow cytometry. RESULT...

Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study

Objectives. Assessment of gemcitabine/carboplatin combination in patients with advanced-stage hepatocellular carcinoma (HCC) in a phase II trial for safety and efficacy. Methods. Forty patients with previously untreated advanced-stage HCC were prospectively enrolled and subjected to gemcitabine/carboplatin regimen which consisted of gemcitabine 1000 mg/m(2) on days 1 and 8, and carboplatin AUC ...